STOCK TITAN

Avenue Therapeutics Inc - ATXI STOCK NEWS

Welcome to our dedicated news page for Avenue Therapeutics (Ticker: ATXI), a resource for investors and traders seeking the latest updates and insights on Avenue Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avenue Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avenue Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.31%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.43%
Tags
Avenue Therapeutics Inc

Nasdaq:ATXI

ATXI Rankings

ATXI Stock Data

5.82M
39.44M
10.88%
2.8%
0.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About ATXI

avenue therapeutics, inc. (nasdaq: atxi), a fortress biotech (nasdaq: fbio) company, is a specialty pharmaceutical company focused on the development and commercialization of intravenous (iv) tramadol for the management of moderate to moderately severe postoperative pain. iv tramadol may fill a gap in the acute pain market between iv acetaminophen/nsaids and iv conventional narcotics. avenue is currently evaluating iv tramadol in a pivotal phase 3 program for the management of postoperative pain.